Xintela has completed its clinical phase I/IIa study in knee osteoarthritis with XSTEM after the last follow-up visit for the last patient. The study included 24 patients who received an injection of the company's stem cell product XSTEM. Earlier interim results showed safety and significant improvements in knee pain and knee function up to 18 months. The final report with 24-month data for the highest dose is expected by the end of September 2025.
|
Published August 15, 2025
Xintela completes clinical knee osteoarthritis study with XSTEM
Notes
Flerie and Lipum enter into merger plan
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
NEWSLETTER
Today's news roundup
News roundup Tuesday, November 18
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account